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Nasopharyngeal carcinoma (NPC) is an epithelial cancer of the nasopharynx which is highly associated with Epstein–Barr virus (EBV).
Worldwide, most of the top 20 countries with the highest incidence and mortality rates of NPC are low- and middle-income countries.
Many studies had demonstrated that EBV could be detected in the tissue, serum and plasma of NPC patients. In this study, we
explored the potential of assays based on non-invasive nasal washings (NW) as a diagnostic and prognostic tool for NPC. A total of
128 patients were evaluated for NW EBV DNA loads and a subset of these samples were also tested for 27 EBV and human miRNAs
shortlisted from literature. EBV DNA and seven miRNAs showed area under the receiver operating characteristic curve (AUC) values of
more than 0.7, suggestive of their potential utility to detect NPC. Logistic regression analyses suggested that combination of two NW
assays that test for EBNA-1 and hsa-miR-21 had the best performance in detecting NPC. The trend of NW EBV DNA load matched with
clinical outcome of 71.4% (10 out of 14) NPC patients being followed-up. In summary, the non-invasive NW testing panel may be
particularly useful for NPC screening in remote areas where healthcare facilities and otolaryngologists are lacking, and may
encourage frequent testing of individuals in the high risk groups who are reluctant to have their blood tested. However, further
validation in an independent cohort is required to strengthen the utility of this testing panel as a non-invasive detection tool for NPC.
Introduction
Nasopharyngeal carcinoma (NPC) is an epithelial cancer of
the nasopharynx. It is highly prevalent in Southeast Asia and
the Southern part of China but very rare in most part of the
world. Family members of NPC patients have four- to eight-
fold higher risk than the general population in developing
NPC.1 According to GLOBOCAN’s estimates, 17 of the
20 countries with highest NPC incidence and mortality rates
worldwide are low- and middle-income countries (LMICs).2
In Malaysia, the group with lowest social class were reported
to have a four-fold higher risk of disease3 and some of the
high incidence regions are in remote areas where access to
healthcare is limited. Majority of NPC cases frequently pre-
sented late4 leading to poor survival rate.5
The aetiology of NPC is a complicated interaction between
genetic, dietary and viral (Epstein Barr Virus [EBV]) factors.6
Reports showed that EBV could be detected in NPC cells
most of the time, while traces of EBV could also be found in
the blood, urine and saliva of NPC patients.7–9 Early detec-
tion tests such as EBV serology, EBV DNA load from naso-
pharyngeal swab/brush and plasma are valuable for NPC
screening and patient management. Recent large cohort NPC
screening studies in Southern China had demonstrated the
utilities of these tests as early detection tool for NPC.10,11
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However, these NPC screening tests have yet to be adopted
in LMICs with high NPC incidence rates due to many rea-
sons. Lack of resources to store and process biospecimen for
screening tests as well as access to endoscopic examination
by otolaryngologists are among some of the reasons. In
LMICs and remote areas, a useful non-invasive test may
encourage frequent testing of individuals from the high risk
groups for early detection and aids in the monitoring of dis-
ease recurrence.
MiRNAs are a group of small non-coding RNAs which alter
gene expression post-transcriptionally12 and its dysregulation
has been identified in many cancers including NPC.13,14 Over
the course of about a decade, miRNA signatures unique to
NPC had been reported based on studies in tissue, serum and
plasma. As discordance between tissue miRNAs and circulating
miRNAs is a known issue15 and it is assumed that miRNAs in
NW samples may be more similar to cellular miRNAs than cir-
culating miRNAs, five published Gene Expression Omnibus
(GEO) datasets were compared to identify miRNAs which were
consistently dysregulated between NPC and control tissues.
Together with EBV DNA loads, levels of selected EBV and
human miRNAs were examined in nasal washings (NW) of
NPC patients and non-NPC patients. The aims of this study
were (i) to evaluate the diagnostic value of NW EBV DNA and
NW miRNAs for NPC and, (ii) to determine if NW EBV DNA




Patients were recruited from the Department of Otorhinolar-
yngology in Selayang Hospital and the Department of Oncol-
ogy and Radiotherapy in Kuala Lumpur Hospital with
informed consent and ethics approval from the Medical
Research and Ethics Committee, Ministry of Health Malaysia.
All NPC patients were histologically diagnosed as NPC while
controls were non-NPC patients from the otorhinolaryngol-
ogy clinic. Details of the non-NPC group are depicted in
Figure 1. Collection of NW sample was carried out by the
patient himself/herself. Five millilitres of saline was pushed
through the left nostril to the right nostril from a syringe and
nasal washings was collected in a kidney dish. The same pro-
cedure was repeated for the right nostril to the left nostril.
The combined nasal washings were then poured into a plastic
bottle and stored at −20 C.
DNA and RNA extractions
Frozen NW samples were thawed and centrifuged at 4000
RPM, 4 C for 20 min. Cell pellets were resuspended with
400 μL of phosphate buffered saline and separated into two
200 μL aliquots for separate extraction of DNA and RNA.
DNA and RNA extractions were performed using QIAamp
DNA Mini kit and miRNeasy Micro Kit (Qiagen, Germany),
respectively, according to manufacturer’s instructions. Syn-
thetic miRNAs (cel-miR-39 and cel-miR-54) were spiked in
during RNA extraction after the addition of lysis buffer.
Quantification of EBV DNA
EBV DNA loads were evaluated by quantifying PCR products
amplified from the BamHI-W region and EBNA-1 of EBV.
Sequences of primers and probes used for the detection of
EBV DNA were according to previous publications,7,16 with
FAM and MGB as fluorochrome and quencher, respectively
for probes. Quantitative Polymerase Chain Reaction (qPCR)
was carried out in triplicates for each sample. No-template-
control and a series of standard points from serial dilution of
Namalwa cells DNA were run in each qPCR plate. EBV DNA
copy number was interpolated from the standard curve and
results were calculated using the following formula:




× elution volume=volume used for qPCRð Þ
(Cq = quantitation cycle, c = intercept, m = slope of the
standard curve)
All EBV DNA positive NW samples with Cq value in only
one qPCR wells and/or out of the interpolation range were
arbitrarily set as one copy EBV DNA.
Evaluation of miRNA expression
Twenty-seven miRNAs were shortlisted from GEO DataSets
for further validation in RT-qPCR (Supporting Information
Table S1). Selection criteria is described in Supporting Infor-
mation Methods.
RNA samples were subjected to reverse transcription (RT),
preamplification and qPCR carried out in triplicates according
What’s new?
Nasopharyngeal carcinoma (NPC) is highly associated with Epstein–Barr virus (EBV) and is mostly prevalent in Southeast Asia.
While EBV serology and EBV DNA load from nasopharyngeal swab or plasma are valuable early detection tests, a lack of
resources has limited their implementation. This study found that the performance of nasal washings EBV DNA testing for the
detection of NPC is superior to urine EBV DNA testing but inferior to EBV DNA testing from nasopharyngeal swab and blood.
Nonetheless, nasal washings testing may be valuable in remote areas lacking healthcare facilities and lower invasiveness may
encourage frequent testing for high-risk groups.
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to the optimised protocol that had demonstrated high consis-
tency of miRNA detection in high-throughput microfluidic plat-
form.17,18 No-template-control and a series of standard points
from serial dilution of pooled human cell/xenograft RNA were
run in the same dynamic array. Assays that did not exhibit lin-
ear amplification and data points that were beyond the reliable
detection limit (Cq > 25) were excluded from analysis. Average
Cq values for NW were normalised to spiked-in synthetic oligo-
nucleotides to remove technical bias.17 For comparison of
miRNA levels between NW samples, fold change over the detec-
tion limit was calculated using the following formula:




Mann Whitney test was applied to compare the differences
between two groups of samples. Area under the curve (AUC)
of receiver operating characteristic (ROC) were calculated to
evaluate the performance of markers as classifier for NPC.
Optimal cut-off values were obtained by calculating Youden’s
index. Logistic regression was used to determine if combina-
tion of markers could lead to improved classifier performance
for NPC.
Results and Discussions
Characteristics of study population
A total of 128 patients comprising of 55 NPC and 73 non-NPC
were assessed for their NW EBV DNA loads and miRNA
levels. Samples collected at multiple time points from 14 NPC
patients and their follow-up information were available for
analysis. Overview of the experimental details is shown in
Figure 1. Between the non-NPC patient samples and pre-
treatment NPC samples, there were no significant differences in
the distribution of age, ethnicity and gender (Supporting Infor-
mation Table S2).
NW EBV DNA load as biomarker for NPC detection and
monitoring
In our study, we showed that even though NW sampling was
carried out by different operators (the test subject himself/her-
self), NW EBV DNA test results were consistent and repro-
ducible (Supporting Information Fig. S1). Pre-treatment NPC
samples were shown to have significantly higher NW EBV
DNA load than the non-NPC samples (Figs. 2a and 2b). ROC
analysis suggested that NW EBV DNA is good at classifying
non-NPC from pre-treatment NPC patients (Fig. 2j and Sup-
porting Information Table S3). Patients with larger tumour
size (T3 and T4) appeared to have higher median of NW EBV
Patients included in the study
n = 128
Non-NPC patients































Figure 1. Overview of experimental design. EBV DNA and microRNAs from the nasal washings (NW) of non-NPC and pre-treatment NPC were
evaluated to develop detection tool for NPC (indicated by solid line). Multiple time points NW samples from NPC patients were included in
the evaluation of EBV DNA as a monitoring tool for NPC (indicated by dashed line). [Color figure can be viewed at wileyonlinelibrary.com]
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DNA load as compared to those with smaller tumour size
(T1 and T2) (Supporting Information Fig. S2). When remis-
sion samples were compared to residual NPC samples, higher
median NW EBV DNA load was seen in the residual NPC
samples (Supporting Information Fig. S3).
Different NW EBV DNA trends were observed in NW sam-
ples collected at multiple time points from 14 NPC patients
(Fig. 3). Among these cases, 71.4% (10/14, Figs. 3a–3j) had
NW EBV DNA trends that corresponded to their clinical out-
comes. Consistently undetectable or decreasing NW EBV
DNA load was observed in eight of the remission cases
(Figs. 3a–3h), while increasing NW EBV DNA load was
observed in a recurrent NPC (Fig. 3i) and a residual NPC
(Fig. 3j). For the case depicted in Figure 3i, follow-up clinical
examination and cytology test of nasal swab reported no malig-












































































































































































































































































Figure 2. EBV DNA load and differentially expressed miRNAs in nasal washings. EBV DNA load measured by (a) BamHI-W and (b) EBNA-1 were
significantly different between pre-treatment NPC samples (n = 46) and non-NPC samples (n = 73) (Mann–Whitney test, **** p ≤ 0.0001).
EBV DNA load was set as 0.1 (arbitrary value) for samples below detection limit (Cq > 40) and 1 to indicate samples that were weak positive.
(c) hsa-miR-21, (d) hsa-miR-26b, (e) hsa-miR-29c, (f ) hsa-miR-93, (g) hsa-miR-205, (h) hsa-miR-375 and (i) hsa-miR-421 in nasal washings of
pre-treatment NPC (n = 35) and non-NPC (n = 64) samples were significantly different (Mann Whitney test, *** p ≤ 0.001; **** p ≤ 0.0001).
( j) Receiver operating characteristics curve discriminating pre-treatment NPC from non-NPC. Area under curve for all markers are above 0.7 as
shown in Supporting Information Table S4. [Color figure can be viewed at wileyonlinelibrary.com]
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case was not clinically diagnosed as recurrence until 10 months
later. For the case shown in Figure 3j, consistent high levels of
NW EBV DNA over two post-treatment sampling time points
corresponded well with the clinical diagnosis of residual NPC.
Among the four cases which NW EBV DNA load did not cor-
respond to the clinical outcome, possible reasons include:
(i) false positive, as the increment was from undetected to one
copy (Fig. 3k), (ii) no tumour in the nasopharynx leading to
negative NW EBV DNA test results even though patients had
distant metastasis (Figs. 3l and 3m) and (iii) possible true EBV
negative for recurrent NPC (Fig. 3n). Limitation of NW EBV
DNA test to detect EBV negative NPC cases suggested the
importance to include non-EBV markers in the detection
panel.
NW miRNA as biomarker for NPC detection
GEO2R analysis on five NPC tissue miRNA profiling data sets
obtained from NCBI GEO database (GSE70790, GSE43039,
GSE32960, GSE36682 and GSE32906) was performed to iden-
tify dysregulated miRNAs in NPC. Thirteen consistently dys-
regulated miRNAs in at least three of the five studies, together
with an additional 14 miRNAs dysregulated in at least one
of the five studies were selected for further validation
(Supporting Information Table S1).
Due to insufficient material, only 35 NPC and 64 non-
NPC samples were evaluated for NW miRNAs. One out of
27 miRNA assays failed and was excluded from further anal-
ysis (Supporting Information Table S1). Among the miRNAs
analysed, 69.3% (18/26) were detected in NW samples. Low
and inconsistent levels of RNU6B, RNU44 and RNU48 in
NW samples (data not shown) suggested that there were lim-
ited cellular RNA and a mixture of cell-free miRNAs from
biofluid within the nasal cavity. As a result, these endogenous
small RNA were not applicable as reference gene for NW
data normalisation. Based on data normalised to cel-miR-39
spike-in controls, RT-qPCR results indicated that 38.9%
(7/18) of the miRNAs detected in NW, namely hsa-miR-21,
hsa-miR-26a, hsa-miR-29c, hsa-miR-93, hsa-miR-205, hsa-
miR-375 and hsa-miR-421 were significantly upregulated in
pre-treatment NPC compared to non-NPC NW samples
(Figs. 2c-2i). In ROC analysis, the AUC of these miRNAs
were all above 0.7 in classifying non-NPC from pre-treat-
ment NPC (Fig. 2j and Supporting Information Table S3).
Levels of hsa-miR-21, hsa-miR-26a, hsa-miR-29c and hsa-
miR-93 appeared to be associated with larger tumour size
(Supporting Information Fig. S2).
Two of the upregulated NW miRNAs, hsa-miR-93 and
hsa-miR-205 concurred with the findings of other studies.19,20
Both hsa-miR-93 and hsa-miR-205 were shown to be upregu-
lated in NPC tissue samples21,22 and could lead to enhance cell
growth, migration and invasion in NPC cell lines.21,23 Mean-
while, hsa-miR-21 and hsa-miR-421 that were shown to be
upregulated in NW were consistent with the trend reported by
1 to 2 NPC tissue profiling studies (Supporting Information
Table S1). Three of the upregulated NW miRNAs, namely
hsa-miR-26a, hsa-miR-29c and hsa-miR-375, were previously
reported to be downregulated in NPC tissues as compared to
control tissues.20,24,25 Discordance of circulating miRNA pro-
files with tissue miRNA profiles is a common issue.15 Studies
of NPC tissues compare cellular miRNAs between tumour
and normal epithelial cells while our study using NW analysed
a mixture of cellular and cell-free miRNAs from tumour, as
well as from other cell types and biofluid within the nasal cav-
ity. Hence differences in levels may also not be directly com-
parable. Nonetheless, we postulate that, just like EBV DNA,
the significantly upregulated NW miRNAs which were associ-
ated with tumour size are highly enriched in tumour cells.
Performance of combined markers for NPC detection
NW EBV DNA and seven microRNAs that were shown to
have significant differences between the pre-treatment NPC
and non-NPC, as well as AUC > 0.7 were included in the
logistic regression analyses. Simple logistic regression demon-
strated that all nine markers (BamHI-W, EBNA-1, hsa-miR-
21, hsa-miR-26a, hsa-miR-29c, hsa-miR-93, hsa-miR-205,
hsa-miR-375 and hsa-miR-421) were able to predict NPC
with p < 0.05 (Supporting Information Table S4). In multiple
logistic regression analyses using forward and backward
methods to evaluate all markers shortlisted from simple
logistic regression analyses, only EBNA-1 and hsa-miR-21
remained as the significant variables in the model. Multicolli-
nearity was detected and moderate correlation was observed
between BamHI-W and EBNA-1, as well as among few
miRNAs, namely hsa-miR-21, hsa-miR-26a, hsa-miR-29c,
hsa-miR-93 and hsa-miR-205. This could have led to the
exclusion of these markers in the model for the prediction of
NPC. Multiple logistic regression model with EBNA-1 and
hsa-miR-21 showed the best AUC (0.860) compared to any
marker alone as a prediction model (Supporting Information
Table S3). The utility of this model needs to be evaluated fur-
ther by performing validation in an independent cohort in
the future which should also include samples from non-NPC
patients with other EBV related diseases and EBV negative
NPC patients.
Comparison of NW test to other less/minimally invasive test
Besides NW samples, EBV DNA test can be carried out using
blood and other less/minimally invasive sample types, including
urine and nasopharyngeal swab/brushings (Supporting Infor-
mation Table S5). Among these sample types, otolaryngologist
is required to collect nasopharyngeal swab/brushings samples,
medical support staff would be needed for blood collection
while collection of urine and NW samples could be done by
the individual with guidance from the medical support person-
nel. The cost for NW sampling is lower compared to blood
and nasopharyngeal swab/brushings samples that require addi-
tional laboratory resources like centrifuge, preservation buffer
and/or storage in ultra-low temperature (−80C). In terms of
2264 Nasal washings biomarkers in NPC
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Figure 3. EBV DNA load in nasal washings of NPC patients collected at multiple time points. Each graph represents the trend of NW EBV DNA
load (measured by EBNA-1 assay) for one patient. Each dot represents NW EBV DNA load at the indicated time point. (a)–(h) Patients were
last known to be well and had decreasing or undetectable NW EBV DNA load after treatment. (i) and ( j) Increasing NW EBV DNA load in
patients with recurrence/residual NPC. (k) Undetectable and weak positive NW EBV DNA load in complete remission patient. (l)–(n)
Undetectable or decreasing NW EBV DNA load in patients with lung metastasis or recurrence. RT, radiotherapy; NAC, neoadjuvant
chemotherapy; AC, adjuvant chemotherapy; CCRT, concurrent chemo-radiotherapy; CT, chemotherapy. [Color figure can be viewed at
wileyonlinelibrary.com]
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test performance as evaluated by sensitivity, specificity, positive
predictive value and negative predictive value, NW EBV DNA
test (EBNA-1) is slightly inferior to nasopharyngeal swab/
brushings EBV DNA test but outperformed the urine EBV
DNA test7 (Supporting Information Table S5), probably due to
the proximity of sampling at the nasopharyngeal area.
Conclusion
In summary, the performance of NW EBV DNA test for the
detection of NPC is superior to urine EBV DNA test but infe-
rior to EBV DNA test from nasopharyngeal swab/brushings
and blood. In remote areas of LMICs with high prevalence of
NPC, access to healthcare facilities and routine monitoring by
otolaryngologists are limited. The advantage of NW EBV
DNA test compared to nasopharyngeal swab/brushings is that
sampling can be easily achieved without the presence of oto-
laryngologist. In addition, high risks groups and post-
treatment NPC patients may feel more inclined to be tested
frequently as compared to blood test because sampling of NW
is non-invasive. In fact, nasal washing is a procedure routinely
taught by the otolaryngologists to the post-treatment NPC
patients for maintenance of nasopharynx. NW test may have
potential as a post-treatment surveillance system where
patients with positive NW results can be closely monitored
for any sign of recurrence. Lastly, our preliminary findings
suggest that NW EBV DNA, hsa-miR-21, hsa-miR-26a, hsa-
miR-29c, hsa-miR-93, hsa-miR-205, hsa-miR-375 and hsa-
miR-421 are potential markers for NPC detection. External
validation is required to confirm their applicability as detec-
tion tool for NPC.
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